Thelansis

 Asthma represents a multifaceted clinical syndrome characterized by variable airflow obstruction, bronchial hyperresponsiveness (BHR), and cellular inflammation. The Global Initiative for Asthma (GINA) defines asthma as a heterogeneous disease primarily marked by airway inflammation. The presence of respiratory symptoms such as wheezing, shortness of breath, chest tightness, and cough, exhibiting variability over time and in intensity, alongside variable expiratory airflow limitation, constitutes the defining features of asthma. This condition results in fluctuating respiratory symptoms and variable airflow limitation, culminating in compromised activity levels, diminished quality of life, and occasional exacerbations, colloquially termed 'asthma attacks.' These exacerbations may necessitate emergency healthcare utilization and hospitalization and, in rare instances, lead to fatalities. Asthma's risk factors encompass genetic, environmental, and host-related elements. Whil...

  Asthma is a chronic inflammatory condition of the airways in which hypertrophy of bronchial smooth muscle and mucous glands with plugging of small airways with thick mucus can occur. This airway inflammation contributes to airway hyper-responsiveness, airflow limitation, and respiratory symptoms and is at the root of the disease's chronic nature. Based on the clinical features classified as mild intermittent, mild persistent, moderate persistent, or severe persistent, depending on symptom frequency and severity and lung function as assessed by forced expiratory volume in 1 second (FEV1). Depending on symptoms, signs, and functional assessment, asthma exacerbations are classified as mild, moderate, severe, and impending respiratory failure. The incidence of Asthma in the USA varies from 158 to 187 cases per 100,000 populations, and the prevalence varies between 6.7 to 8.5 across all ages. Thelansis’s “Asthma Market Outlook, Epidemiology, Competitive Landscape , an...

  Asthma is a chronic inflammatory condition of the airways in which hypertrophy of bronchial smooth muscle and mucous glands with plugging of small airways with thick mucus can occur. This airway inflammation contributes to airway hyper-responsiveness, airflow limitation, and respiratory symptoms and is at the root of the disease's chronic nature. Based on the clinical features classified as mild intermittent, mild persistent, moderate persistent, or severe persistent, depending on symptom frequency and severity and lung function as assessed by forced expiratory volume in 1 second (FEV1). Depending on symptoms, signs, and functional assessment, asthma exacerbations are classified as mild, moderate, severe, and impending respiratory failure. The incidence of Asthma in the USA varies from 158 to 187 cases per 100,000 populations, and the prevalence varies between 6.7 to 8.5 across all ages The competitive landscape of Asthma includes country-specific approved and pipeline therap...